Jan 13, 2023 15:06 JST

Source: Eisai

Eisai Launches Renewed Sustainability Page

TOKYO, Jan 13, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced that it has renewed the Sustainability page of its corporate website and it is now accessible to the public.

 


Sustainability Top Page
www.eisai.com/sustainability/index.html

The Eisai's Corporate Concept is "to give first thought to patients and the people in the daily living domain, and to increase the benefits that health care provides to them". Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. For realizing our corporate concept, it is necessary to implement corporate measures based on a long-term perspective under a well-cultivated governance structure. Therefore, it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues.

In order to provide information about our sustainability approach and activities in an easy-to-understand manner, we have enhanced the content, and renewed the key visuals, design and page structure. We have also featured our approach, targets and initiatives for improving access to medicines, which Eisai is focusing on, as well as the areas of environment, society and governance.

Through further efforts in our proactive disclosure of information for sustainability, we will aim to develop and maintain favorable relations with all of our stakeholders.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
March 24 2023 12:22 JST
 
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
March 23 2023 12:30 JST
 
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal
March 20 2023 10:18 JST
 
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease
March 14 2023 10:09 JST
 
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award
March 10 2023 14:04 JST
 
Eisai Certified as a 2023 Health and Productivity Management Outstanding
March 09 2023 08:07 JST
 
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
March 06 2023 09:58 JST
 
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan
March 02 2023 09:45 JST
 
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 28 2023 14:28 JST
 
Dissolution of Bracco-Eisai Joint Venture
February 21 2023 13:02 JST
 
More Press release >>

Latest Press Release


More Latest Release >>